MEDICINES FOR EUROPE has 88 disclosed EU lobbying meetings from 2024-09-17 to 2026-05-19: 25 with the European Commission and 63 with Members of the European Parliament. Source: EU Transparency Register no. 48325781850-28, Commission disclosures and MEP declarations. Methodology
MEDICINES FOR EUROPE
EU lobbying footprint — who they meet, and on what.
- Register no.
- 48325781850-28 ↗
- Disclosed meetings
- 88 (25 Commission · 63 MEP)
- Period
- 2024-09-17 → 2026-05-19
Declared fields of interest: Budget · Business and industry · Climate action · Communication · Competition · Consumers · Customs · Digital economy and society · Economy, finance and the euro · Education and training · Employment and social affairs · Enlargement
Lobbying profile
as declared 2026-05-12- Category
- Trade and business associations
- Legal status
- AISBL
- Declared lobbying cost
- €500,000
- Lobbying FTEs
- 7.95
- Members
- 4
At a glance
- Health14
- Technology3
- Industry1
- Ulla Schwager4
- Olga Solomon3
- Olivér Várhelyi3
- Jana Dabbelt1
- Paula Duarte Gaspar1
Disclosed meetings
Newest first, showing the most recent 60 of 88. EC = European Commission, EP = Member of the European Parliament.
- avloppsdirektivetsource ↗
- Biotech Actsource ↗
- 2026-05-04ECOlga Solomon · Head of Unit- challenges for generic and biosimilar applicants in accessing reference products - clear guidelines on use of reference data for ERAsource ↗
- Urban Wastewater Treatment Directivesource ↗
- Biotech Actsource ↗
- 2026-04-16ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiHealth industry roundtablesource ↗
- Biotech Actsource ↗
- Biotech Actsource ↗
- Urban Waste Water Directivesource ↗
- EU Biotech Act Isource ↗
- 2026-03-25ECPaula Duarte Gaspar · Head of UnitExtended Producer Responsibility under the recast Urban Wastewater Treatment Directivesource ↗
- Exchange of views on Biotech Actsource ↗
- 2026-03-17ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiCurrent pharma matterssource ↗
- SANT Committeesource ↗
- 2026-03-16ECGiulia Del Brenna · Head of UnitSubject matters relevant to the pharmaceutical industry in particular those in which DG GROW is involved.source ↗
- Critical medicines actsource ↗
- EU Biotech Actsource ↗
- The Critical Medicines Act and the Future of Access to Essential Medicines in the EUsource ↗
- pharmaceutical policysource ↗
- Biotech, UWWTDsource ↗
- 2026-03-04ECPernille Weiss-Ehler · Cabinet of Commissioner Jessika RoswallUWWTD- the Urban Wastewater Treatment Directivesource ↗
- 2026-02-24ECUlla Schwager · Head of UnitRecent policy developments concerning the pharmaceutical industriessource ↗
- 2026-02-17ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiBiotech Act, Pharma package, CMAsource ↗
- 2026-02-09ECOlivier Girard · Head of UnitExchange of views on health security, civ-mil cooperation and competitiveness considering the current geopolitical situation.source ↗
- Exchange of views on Cardiovascular Strategysource ↗
- CMA + Health policysource ↗
- Urban Waste Water Treatment Directivesource ↗
- 2026-01-16ECPatrick Child · Deputy Director-GeneralPFAS letter /UWWT studysource ↗
- Health Policysource ↗
- 2026-01-12ECRainer Becker · DirectorThe meeting took place upon request of MfE to discuss a PFAS restriction under REACH, the Urban Waste Water Treatment Directive (UWWTD), the Biotech Act and the Critical Medicines Act (CMA)source ↗
- Review of the EU General Pharmaceutical Legislationsource ↗
- 2025-11-24ECUlla Schwager · Head of UnitDiscussion on the practical implications of the environmental risk assessmentsource ↗
- Critical Medicines Actsource ↗
- 2025-10-15ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiCompetitiveness of EU generic pharma industrysource ↗
- Pharmaceutical legislationsource ↗
- 2025-10-03ECOlga Solomon · Head of UnitThe discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition.source ↗
- Critical Medicines Actsource ↗
- To discuss Critical Medicines Actsource ↗
- 2025-09-15ECPaul Speight · Head of UnitREACH and Universal PFAS restrictionsource ↗
- The EU Critical Medicines Actsource ↗
- Shaping the Future of EU Pharmaceutical Legislationsource ↗
- Critical Medicines Actsource ↗
- Revision of the EU Pharmaceutical Directivesource ↗
- Critical Medicines Actsource ↗
- Critical Medicine Act Reportsource ↗
- Critical Medicines Act / generic, biosimilar and value added medicinessource ↗
- European Health Policy - Critical Medicines Actsource ↗
- Pharma Packagesource ↗
- Critical Medicines Actsource ↗
- critical medicinessource ↗
- Exchange of views on Critical Medicines Actsource ↗
- Pharma Packagesource ↗
- 2025-06-26ECPatricia Reilly · Cabinet of President Ursula von der Leyenexchange with the Medicines for Europe Executive Committeesource ↗
- Resilient Health Unionsource ↗
- General Pharmaceutical Legislation Reviewsource ↗
- Pharmaceutical packagesource ↗
- Meeting with Medicines for Europesource ↗
- Critical Medicines Actsource ↗
- 2025-06-02ECFlorika Fink-Hooijer · Director-GeneralBreakfast on the margins of HERA Industry Dayssource ↗
- Urban Waste Water Directivesource ↗
Lobbying in these areas
Frequently asked
How many EU lobbying meetings has MEDICINES FOR EUROPE disclosed?
MEDICINES FOR EUROPE (EU Transparency Register no. 48325781850-28) appears in 88 disclosed meetings with EU officials and MEPs between 2024-09-17 and 2026-05-19: 25 with the European Commission and 63 with Members of the European Parliament.
What does MEDICINES FOR EUROPE lobby on?
MEDICINES FOR EUROPE's disclosed EU meetings most often concern Health, Technology, Industry. Every meeting and its topic is listed with its official source on this page.
Who does MEDICINES FOR EUROPE meet in Brussels?
Across its disclosed meetings, MEDICINES FOR EUROPE has met Commission officials including Ulla Schwager, Olga Solomon, Olivér Várhelyi, and MEPs including METZ Tilly, MONTSERRAT Dolors, KNOTEK Ondřej. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
- EU Transparency Register profile (no. 48325781850-28) ↗
- European Commission meeting disclosures ↗
- European Parliament — MEP meeting declarations ↗
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.